Jon W Walker, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 2202 Us Highway 380, Suite 112, Bridgeport, TX 76426 Phone: 940-683-2338 Fax: 940-683-2394 |
Jon Wayne Copeland, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 808 Woodrow Wilson Ray Cir, Bridgeport, TX 76426 Phone: 940-683-2297 Fax: 940-683-2984 |
Dr. Mihir Umesh Talati, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1905 Doctors Hospital Dr, Bridgeport, TX 76426 Phone: 940-683-0400 |
Timothy W Mcintyre, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 411 N Lake Shore Cir, Bridgeport, TX 76426 Phone: 940-210-8275 |
David A. Ray, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 808 Woodrow Wilson Ray Cir, Bridgeport, TX 76426 Phone: 940-683-2297 Fax: 940-683-2984 |
Christine Marie Cox, APRN Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 401 Center Court Dr, Bridgeport, TX 76426 Phone: 940-255-6552 |
Dr. Charles Leslie Majka, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1306 13th St, Bridgeport, TX 76426 Phone: 940-683-5287 Fax: 940-683-4382 |
News Archive
Cerebral palsy is a neurodevelopmental condition that affects motor function, more often in children born prematurely. Because cerebral palsy is a result of brain injury received shortly before, during, or soon after birth, the number of infants being diagnosed with the condition is a good indicator of the quality of perinatal and neonatal care.
Researchers analysed hospital discharge records for Scottish residents aged at least 18 years with a first emergency hospitalisation for heart attack, angina, or other chest pain between 1990 and 2000.
A new treatment for patients with a form of congenital retinal blindness has shown success in improving vision, according to results published today in Nature Medicine led by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania.
Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced that it has received commitments from institutional investors to purchase $50 million of securities in a registered direct offering.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported updated data from a pivotal trial of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic anaplastic large cell lymphoma.
› Verified 6 days ago